PATENT CLAIM ANALYSIS

Application Number: 16001318
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-11
Patent Classification: ["514", "001000"]

Abstract:
The present disclosure in various embodiments teaches methods of treating patients in need of treatment with a Factor Xa inhibitor, and who are also concomitantly administered verapamil.

Claim (Index 17):
The method of  claim 16 , wherein the dose of rivaroxaban administered in step (b) is selected from the group consisting of about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, and about 12.5 mg.

Metadata:
- Claim Count in Document: 87.0
- Percentile: 94.0
- Lexical Diversity: 1.07407
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13128459', '13184704', '13454286', '13454255', '12688038']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7738149937866121
- 35 USC 102 Novelty (BERT): 0.515859680302398
- Combined Prediction Score: 0.7480194624381907
- Mean Citation Score: 244.7395
- Max Citation Score: 258.22217
- Similarity Product: 164.9864972023976

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test